Dr Iain Oswald

Senior Lecturer

Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

EPSRC Early Career Fellow

Iain D.H. Oswald graduated from the University of Edinburgh (2001) and remained there in the group of Professor Simon Parsons to study hydrogen-bonding patterns and co-crystallisation as part of his PhD. Fortunately, this research expanded to investigate the effects of high pressure which allowed him the opportunity to work at the European Synchrotron Radiation Facility in Grenoble. In 2004 he left for Grenoble where he became a postdoctoral researcher on the high pressure beamline (ID27). In 2006, he returned to Edinburgh to join the group of Colin R. Pulham and started a fellowship position funded by the Leverhulme Trust.

In 2009, Iain started his post at SIPBS as a Lecturer in Pharmaceutics and is interested and has been awarded funding in the areas of co-crystallisation of pharmaceutical materials at high pressure (EPSRC Early Career Fellowship) and polymorphism and polymerisation of monomeric materials (Leverhulme Trust 2012-2015). 

Iain has contributed to the MPharm program as the 4th Year Co-ordinator (2012-2016) and has been an integral part of the redevelopment of the MPharm curriculum.  He lectures and is class coordinator for the 2nd year class Pharmaceutics and for the Year 2 class Normal Function of the gastrointestinal tract.  Students in the 4th year of study will be able to work with Iain on research associated with pharmaceutical products in the solid state. His teaching activities extend to postgraduate degrees in the MRes Drug Delivery Systems and MSc Pharmaceutical Analysis course.

He is currently a member of the ESPRC Early Career Forum in Manufacturing that seeks engage with the EPSRC, Industry and academia to highlight challenges in the area of Manufacturing.

Publications

From discovery to scale-up: alpha-lipoic acid : nicotinamide co-crystals in a continuous oscillatory baffled crystalliser
Zhao Lihua, Raval Vishal, Briggs Naomi E B, Bhardwaj Rajni M, McGlone Thomas, Oswald Iain D H, Florence Alastair J
CrystEngComm Vol 16, pp. 5769-5780 (2014)
https://doi.org/10.1039/c4ce00154k
Drug solid solutions - a method for tuning phase transformations
Delori Amit, Maclure Pauline, Bhardwaj Rajni M, Johnston Andrea, Florence Alastair J, Sutcliffe Oliver B, Oswald Iain D H
CrystEngComm Vol 16, pp. 5827-5831 (2014)
https://doi.org/10.1039/c4ce00211c
Putting the squeeze on mephedrone hydrogen sulfate
Satthaphut Natsiri, Sutcliffe Oliver B, Oswald Iain D H
Zeitschrift fur Kristallografie Vol 229, pp. 101-111 (2014)
https://doi.org/10.1515/zkri-2013-1639
Investigation of acrylic acid at high pressure using neutron diffraction
Johnston Blair F, Marshall William G, Parsons Simon, Urquhart Andrew J, Oswald Iain D H
Journal of Physical Chemistry B Vol 118, pp. 4044-4051 (2014)
https://doi.org/10.1021/jp502095n
Beta-adrenoceptor antagonists affect amyloid nanostructure; amyloid hydrogels as drug delivery vehicles
Mains Jen, Lamprou Dimitrios, McIntosh Lisa, Oswald Iain, Urquhart Andrew
Journal of the Chemical Society, Chemical Communications Vol 49, pp. 5082-5084 (2013)
https://doi.org/10.1039/C3CC41583J
Exploring the experimental and computed crystal energy landscape of olanzapine
Bhardwaj Rajni M, Price Louise S, Price Sarah L, Reutzel-Edens Susan M, Miller Gary J, Oswald Iain D H, Johnston Blair F, Florence Alastair J
Crystal Growth and Design Vol 13, pp. 1602-1617 (2013)
https://doi.org/10.1021/cg301826s

more publications

Professional activities

Polymorphism of acrylamide facilitated by pressure-transmitting medium
Speaker
18/6/2018
Under pressure to react - acetylenedicarboxylic acid polymerisation
Speaker
28/8/2017
SciX 2015
Invited speaker
27/9/2015
BCA Chemical Crystallography Group Meeting
Organiser
18/11/2015
BCA Industrial group meeting
Invited speaker
12/11/2015
IUCr 2014 International Union of Crystallography Congress
Participant
3/8/2014

more professional activities

Projects

assess the potential for API particle shape control in API crystallisation processes (Student Placement Lauren Connor)
Oswald, Iain (Principal Investigator)
Period 13-Nov-2017 - 31-Mar-2018
Evaluation of solid-state form for polymer drug delivery
Oswald, Iain (Principal Investigator)
Period 01-Jan-2017 - 31-Dec-2017
Doctoral Training Partnership (DTP - University of Strathclyde) | Bebiano, Suse Vanessa
Oswald, Iain (Principal Investigator) Ter Horst, Joop (Co-investigator) Bebiano, Suse Vanessa (Research Co-investigator)
Period 01-Oct-2015 - 01-Apr-2019
Allergan - Preliminary test
Oswald, Iain (Principal Investigator)
Period 02-May-2016 - 01-Jun-2016
Co-crystallisation consultancy
Oswald, Iain (Principal Investigator)
Period 01-Dec-2015 - 01-Apr-2016
Doctoral Training Centre In Continuous Manufacturing And Crystallisation | Turner, Alice
Halbert, Gavin (Principal Investigator) Oswald, Iain (Principal Investigator) Florence, Alastair (Co-investigator) Johnston, Blair (Co-investigator) Turner, Alice (Research Co-investigator)
Oral drug delivery is currently the preferred method of administration, making up 50% of the market, as it is relatively inexpensive and often has higher patient compliance than other methods. However, not all drugs are ideally suited to this method of administration, as many exhibit poor solubility or poor permeability, as observed in Class II and IV, and, III and IV of the Biopharmaceutical Classification System (BCS) respectively. Drugs with poor solubility are of particular concern as they often fail to fully dissolve in the gastrointestinal fluid and thus their absorption into the systemic circulation can be intermittant and insufficient leading to a greater risk of underdosing, poor bioavailability and diminished therapeutic effect. This can result in poor patient compliance as a result of breakthrough symptoms. However, for BCS Class II drugs it has been found that increased solubility exerted by a solid state modification or formulation can often result in bioavailability similar to that of the more soluble Class I drugs. Although a number of methods to increase solubility already exist there is a need for dosage forms which reduce the damage to the drug and are more flexible to the needs of the patient. Also in terms of the work of CMAC, there is a growing need for continuous methods of dosage form manufacture to reduce costs to the pharma and increase the overall quality of the final product. As such the current study aims to find an innovative formulation method to increase the solubility of pooly soluble drugs. This may be achieved by dramatically changing the way many oral dosage forms are manufactured currently. With a view to reducing the risk of polymorphic changes and degradation, the conventional steps of granulation, drying and compression will be replaced. Dosage forms will be produced by inkjet printing using an aerosol jet printer which has never been used in the pharma field before. It is hoped this will give production a degree of precision with regards to drug distribution, and thus release and overall performance, unrivaled by conventional techniques. It is hoped this will allow the resultant dosage forms to be tailored to the needs of the patient in terms of release time and dose. Due to the reduced number of processing steps and the fact the system can be used in an entirely continuous manner it is hoped this will result in less damage to the drug and a better quality of product. Previous studies have found inkjet printing to be very effective in solibilising class II drugs so it is hoped that the current study will follow this trend.
Period 01-Oct-2014 - 01-Oct-2018

more projects

Address

Strathclyde Institute of Pharmacy and Biomedical Sciences
Robertson Wing

Location Map

View University of Strathclyde in a larger map